Mito-TEMPO improves survival rates in npc1-knockout zebrafish by reducing oxidative stress and enhancing mitophagy via Sod2.
Targeting mitochondrial stress extended survival in a zebrafish model of a fatal ultra-rare brain disease, suggesting the first potential disease-modifying approach.
Published in Science Advances, this study uses an npc1-knockout zebrafish model (the most practical in vivo NPC1 model available) to demonstrate that mitochondrial oxidative stress is a key driver of the fatal neurodegeneration in this ultra-rare lysosomal storage disease. Mito-TEMPO supplementation extended survival by restoring mitochondrial quality control via the SOD2/mitophagy axis, providing therapeutic proof-of-concept for a condition that currently has no disease-modifying treatment.
What the study was
- Study design
- mechanistic_preclinical_in_vivo
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Sci Adv
Why it surfaced
NPC1 is an ultra-rare pediatric fatal disease with extreme unmet need; mitochondrial oxidative stress is a novel and druggable mechanism; Mito-TEMPO is an accessible compound; Sci Adv publication quality; may inform clinical trial of mitochondria-targeting antioxidants in NPC1.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.